Govt in talks with Johnson & Johnson for its single dose vaccine
New Delhi: After permitting Moderna’s COVID-19 vaccine under Emergency use Authorization (EUA), the government of India is in talks with another US vaccine manufacturer ‘Johnson & Johnson’ regarding their single dose vaccine.
“We are in talks with Johnson & Johnson regarding their single-dose vaccine. Their vaccine is being produced outside. As per the plan, this vaccine will also be produced in Hyderabad’s Bio E. We hope the vaccine will be available soon” said Dr. VK Paul, Member-Health, Niti Aayog.
On July 1, Johnson & Johnson said that its single-shot COVID-19 vaccine ‘Janssen’ generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date.
The single-dose vaccine is compatible with standard vaccine storage and distribution channels with ease of delivery to remote areas. The vaccine is estimated to remain stable for two years at -4°F (-20°C), and a maximum of 4.5 months at routine refrigeration temperatures of 36° to 46°F (2° to 8°C).